Published in Hepatology on January 18, 2013
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer | NCT00073307
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma | NCT00108953
Overview and recent trends of systematic reviews and meta-analyses in hepatology. Clin Mol Hepatol (2014) 1.04
A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib. United European Gastroenterol J (2015) 0.87
Management of hepatocellular carcinoma: an overview of major findings from meta-analyses. Oncotarget (2016) 0.81
Metronomic capecitabine in patients with hepatocellular carcinoma unresponsive to or ineligible for sorafenib treatment: report of two cases. Hepat Mon (2013) 0.81
Angiogenesis and Fibrogenesis in Chronic Liver Diseases. Cell Mol Gastroenterol Hepatol (2015) 0.76
Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib. United European Gastroenterol J (2015) 0.75
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med (1999) 17.03
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (2007) 9.44
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA (2011) 6.14
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA (2010) 4.71
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer (2007) 4.22
Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology (1992) 4.22
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 3.65
Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med (1988) 3.53
The course of patients after variceal hemorrhage. Gastroenterology (1981) 3.33
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer (2011) 2.81
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol (2009) 2.69
Epidemiology of hepatocellular carcinoma in USA. Hepatol Res (2007) 2.56
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol (2009) 2.53
Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol (2003) 2.46
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 2.38
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol (2009) 2.17
Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci (2007) 2.01
Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2011) 1.52
Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol (2010) 1.45
Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study. Dig Liver Dis (2005) 1.41
Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol (2003) 1.41
Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer (2008) 1.25
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol (2010) 1.24
A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer (2010) 1.23
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer (2010) 1.22
A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol (2011) 1.17
Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist (2010) 1.16
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer (2010) 1.15
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemother Pharmacol (2009) 1.06
Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest New Drugs (2006) 1.06
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res (2009) 1.04
A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Invest New Drugs (2008) 1.04
Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur J Cancer (2008) 1.03
Prevention of initial variceal hemorrhage. Gastroenterol Clin North Am (1992) 0.99
An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Invest New Drugs (2010) 0.94
Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma. Cancer Sci (2010) 0.94
Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma. Gastrointest Cancer Res (2011) 0.92
Chemotherapy with etoposide, doxorubicin, cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma. Med Oncol (2007) 0.91
Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial. Am J Clin Oncol (2008) 0.91
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. Br J Cancer (2010) 0.88
Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. Cancer (2010) 0.88
A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma. Cancer Chemother Pharmacol (2008) 0.87
Phase II study of imatinib in unresectable hepatocellular carcinoma. Am J Clin Oncol (2008) 0.86
Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria. J Hepatol (2009) 0.83
Benefit of combination β-blocker and endoscopic treatment to prevent variceal rebleeding: a meta-analysis. World J Gastroenterol (2010) 0.83
A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. J Cancer Res Clin Oncol (2008) 0.81
Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial. Am J Clin Oncol (2012) 0.80
Phase II trial of gemcitabine in combination with cisplatin in inoperable or advanced hepatocellular carcinoma. Ann Acad Med Singapore (2008) 0.80
A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma. Invest New Drugs (2008) 0.78
A Phase II study of 5-fluorouracil and cisplatin systemic chemotherapy for inoperable hepatocellular carcinoma with α fetoprotein as a predictive and prognostic marker. Mol Med Rep (2011) 0.77
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology (2008) 4.23
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res (2005) 2.78
Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol (2011) 2.61
Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology (2008) 2.56
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology (2009) 2.45
Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma. Cell Rep (2013) 2.24
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J Hepatol (2013) 1.80
Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood (2011) 1.67
Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology (2002) 1.57
CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice. J Immunol (2010) 1.57
Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res (2004) 1.42
Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer (2003) 1.32
The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int (2014) 1.29
S100A9 a new marker for monocytic human myeloid-derived suppressor cells. Immunology (2012) 1.28
Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma. Immunology (2009) 1.25
Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology (2014) 1.16
Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatology (2014) 1.15
Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth. Clin Cancer Res (2012) 1.09
Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10. Gut (2013) 1.06
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol (2012) 1.01
Immune responses in hepatocellular carcinoma. Dig Dis (2010) 0.97
Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. Cancer Immunol Immunother (2012) 0.96
Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scand J Gastroenterol (2011) 0.96
Anti-Gr-1 antibody depletion fails to eliminate hepatic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol (2012) 0.95
Maintenance of peritoneal B-1a lymphocytes in the absence of the spleen. J Immunol (2004) 0.93
Immune suppression: the hallmark of myeloid derived suppressor cells. Immunol Invest (2012) 0.93
Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses. Cancer Res (2006) 0.93
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol (2010) 0.92
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. Blood (2013) 0.92
Necrotic tumor cell death in vivo impairs tumor-specific immune responses. J Immunol (2007) 0.92
Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival. Hepatobiliary Pancreat Dis Int (2007) 0.90
Tumour-associated transcripts and EGFR deletion variants in colorectal cancer in primary tumour, metastases and circulating tumour cells. Cell Oncol (2008) 0.90
Critical appraisal of clinical practice guidelines for diagnosis and treatment of hepatocellular carcinoma. J Gastroenterol Hepatol (2011) 0.88
Human CCR4+ CCR6+ Th17 cells suppress autologous CD8+ T cell responses. J Immunol (2012) 0.87
Immunotherapy of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol (2010) 0.86
Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration. Cancer Biol Ther (2012) 0.86
Tumor-associated gene expression in disseminated tumor cells correlates with disease progression and tumor stage in colorectal cancer. Anticancer Res (2007) 0.86
IFN-γ regulates survival and function of tumor-induced CD11b+ Gr-1high myeloid derived suppressor cells by modulating the anti-apoptotic molecule Bcl2a1. Eur J Immunol (2014) 0.86
Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer. Mol Oncol (2008) 0.85
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'. Anticancer Drugs (2010) 0.84
Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma. Dig Dis (2012) 0.84
Hazard ratios in cancer clinical trials--a primer. Nat Rev Clin Oncol (2012) 0.83
Pancreatic Squamous Cell Carcinoma: A Population-Based Study of Epidemiology, Clinicopathologic Characteristics and Outcomes. Pancreas (2016) 0.83
Lipopolysaccharide-mediated mast cell activation induces IFN-gamma secretion by NK cells. J Immunol (2010) 0.82
Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells. Immunology (2007) 0.81
Bevacizumab and breast cancer: the E2100 outlier. Lancet Oncol (2010) 0.81
The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. J Clin Endocrinol Metab (2014) 0.80
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. BMC Cancer (2014) 0.79
Peptidases released by necrotic cells control CD8+ T cell cross-priming. J Clin Invest (2013) 0.79
Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature. Support Care Cancer (2014) 0.79
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104. Acta Oncol (2015) 0.79
Hepatic myeloid-derived suppressor cells in cancer. Cancer Immunol Immunother (2015) 0.78
Personalized oncology in interventional radiology. J Vasc Interv Radiol (2013) 0.78
Primary sterile necrotic cells fail to cross-prime CD8(+) T cells. Oncoimmunology (2012) 0.78
Immunogenicity of necrotic cell death. Cell Mol Life Sci (2014) 0.77
Tumor-induced CD11b(+) Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent manner. Eur J Immunol (2015) 0.77
Identification of a novel murine pancreatic tumour antigen, which elicits antibody responses in patients with pancreatic carcinoma. Immunology (2009) 0.77
Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development. Cancer J (2009) 0.76
Myeloid-derived suppressor cells in pancreatic cancer: more than a hidden barrier for antitumour immunity? Gut (2014) 0.76
In reply. Dtsch Arztebl Int (2014) 0.75
Locally advanced cancer of the esophagus, current treatment strategies, and future directions. Front Oncol (2012) 0.75
Mycosis fungoides with involvement of the larynx after liver transplantation in an adult. Am J Gastroenterol (2010) 0.75
Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma. Digestion (2017) 0.75